Public markets saw renewed interest in biotech this week as multiple drugmakers completed IPOs, collectively raising close to $1 billion. Companies including Agomab Therapeutics and Eikon Therapeutics priced offerings that drew investor demand, though some shares softened in the aftermarket on initial trading. Dealflow included smaller wins—Veradermics and SpyGlass also saw first‑day activity—and filings from other developers signaled further planned listings. The flurry marks a shift from the low IPO volumes of prior years and suggests institutional appetite returning for select clinical‑stage names. Underwriters and executives said the pipeline mix—small molecules, bispecifics, and genomic platforms—helped attract capital, but market volatility and execution risk kept post‑deal performance uneven. The week’s activity will be watched as a barometer for whether the biotech IPO thaw has structural legs.